- AstraZeneca Plc's AZN bispecific antibody derived from Compugen Ltd's CGEN COM902 will advance into clinical development.
- AstraZeneca plans to initiate a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer.
- COM902 was licensed to AstraZeneca in 2018 exclusively to develop bispecific and multi-specific antibody products, with AstraZeneca responsible for all research, development, and commercial activities.
- Compugen retains all other rights to the program, except those licensed to AstraZeneca.
- Price Action: CGEN shares are down 1.51% at $5.89, and AZN stock is up 0.42% at $59.69 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsSmall CapGeneralBriefsNon-Small Cell Lung CancerPhase 1 Trial
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
